A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Abstract Text:

J M O'Sullivan,A R Norman,V R McCready,G Flux,F M Buffa,B Johnson,J Coffey,G Cook,J Treleaven,A Horwich,R A Huddart,C C Parker,D P Dearnaley,

PURPOSE: We investigated the potential for improvement in disease control by use of autologous peripheral blood stem cell transplant (PBSCT) to permit administration of high activities of (186)Re-hydroxyethylidene diphosphonate (HEDP) in patients with progressive hormone-refractory prostate cancer (HRPC). METHODS: Eligible patients had progressive HRPC metastatic to bone, good performance status and minimal soft tissue disease. Patients received 5,000 MBq of (186)Re-HEDP i.v., followed 14 days later by PBSCT. Response was assessed using PSA, survival, pain scores and quality of life. RESULTS: Thirty-eight patients with a median age of 67 years (range 50-77) and a median PSA of 57 ng/ml (range 4-3,628) received a median activity of 4,978 MBq (186)Re-HEDP (range 4,770-5,100 MBq). The most serious toxicity was short-lived grade 3 thrombocytopenia in 8 (21%) patients. The median survival of the group is 21 months (95%CI 18-24 months) with Kaplan-Meier estimated 1- and 2-year survival rates of 83% and 40% respectively. Thirty-one patients (81%, 95% CI 66-90%) had stable or reduced PSA levels 3 months post therapy while 11 (29%, 95% CI 15-49%) had PSA reductions of >50% lasting >4 weeks. Quality of life measures were stable or improved in 27 (66%) at 3 months. CONCLUSION: We have shown that it is feasible and safe to deliver high-activity radioisotope therapy with PBSCT to men with metastatic HRPC. Response rates and survival data are encouraging; however, further research is needed to define optimal role of this treatment approach.

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Publishing Authors By Initials

JM O'Sullivan,AR Norman,VR McCready,G Flux,FM Buffa,B Johnson,J Coffey,G Cook,J Treleaven,A Horwich,RA Huddart,CC Parker,DP Dearnaley,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: European journal of nuclear medicine and molecular

VOLUME: 33

Page Numbers: 1055-61

Journal Abbreviation:

ISSN: 1619-7070

DAY: 30

MONTH: 03

YEAR: 2006

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101140988

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.

AFFILIATION: Department of Oncology, Queen's University Belfast/Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, UK. joe.osullivan@qub.ac.uk

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Nucl Med Mol Imaging

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone Related Publications

• A Comparison of Treatment Planning Techniques Used in Two Randomised UK External Beam Radiotherapy Trials for Localised Prostate Cancer.
• A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy.
• A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
• Accelerated chemotherapy in the treatment of urothelial cancer.
• Accuracy and Reproducibility of Conformal Radiotherapy using Data from a Randomised Controlled Trial of Conformal Radiotherapy in Prostate Cancer (MRC RT01, ISRCTN47772397).
• Additional treatment for pT3 prostate cancer: now, later or never.
• An evaluation of Beam cath in the verification process for prostate cancer radiotherapy.
• Current opinion on adjuvant and salvage treatment after radical prostatectomy.
• Distortion-corrected T2 weighted MRI: a novel approach to prostate radiotherapy planning.
• Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy.
• Hypofractionation in clinical trials for prostate cancer.
• Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial.
• Prostate cancer: pelvic nodes revisited--sites, incidence and prospects for treatment with radiotherapy.
• Question of Dose, Fractionation and Technique: Ingredients for Testing Hypofractionation in Prostate Cancer - the CHHiP Trial.
• Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer.
• The utility of digital rectal examination after radical radiotherapy for prostate cancer.
• Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy.